ArticleDiabetology & metabolic syndrome2026
Continuous glucose monitoring-derived glycemic variability and low skeletal muscle mass in middle-aged and older adults with type 2 diabetes mellitus: an analysis using AWGS 2025 criteria.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe impact of glycemic variability (GV) on muscle mass in type 2 diabetes mellitus (T2DM) remains unclear under the updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria. We investigated the association between continuous glucose monitoring (CGM)-derived GV and low skeletal muscle mass (LSMM).
methodsThis cross-sectional study included 614 hospitalized T2DM patients aged ≥ 50 years. GV metrics (SD, MODD, LAGE, and CV) were derived from 7-day CGM data. LSMM was identified using bioelectrical impedance analysis based on age-specific AWGS 2025 thresholds. Multivariate logistic regression, restricted cubic splines (RCS), subgroup, and mediation analyses were performed.
resultsPatients with LSMM exhibited significantly higher GV. In fully adjusted models, higher SD (OR = 1.36), MODD (OR = 1.38), and LAGE (OR = 1.08) were independently associated with increased LSMM risk (all p < 0.05). RCS analysis revealed a linear dose-response relationship between GV and LSMM. Subgroup analyses demonstrated consistent associations across BMI, eGFR, sex, age and HbA1c categories (all p for interaction > 0.05). Mediation analysis indicated that insulin sensitivity-related indices (HOMA2-IR) partially mediated the GV-LSMM relationship.
conclusionsElevated GV is independently associated with LSMM in middle-aged and older adults with T2DM, showing a linear dose-response pattern consistent across diverse clinical profiles. Strategies targeting glucose fluctuations may be crucial for preserving muscle mass in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.